By Mill Chart
Last update: Oct 23, 2023
Groth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if ALKERMES PLC (NASDAQ:ALKS) is suited for growth investing, while it is forming a base and may be ready to breakout. Investors should of course do their own research, but we spotted ALKERMES PLC showing up in our growth with base formation screen, so it may be worth spending some more time on it.
ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:ALKS has earned a 8 for growth:
Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:ALKS has achieved a 6 out of 10:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:ALKS has achieved a 6:
Alongside the Technical Rating, ChartMill assigns a Setup Rating to evaluate the consolidation level of a stock. This rating, ranging from 0 to 10, is updated daily and considers various short-term technical indicators. The current setup rating for NASDAQ:ALKS is 7:
ALKS has a bad technical rating, but it does show a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. There is a support zone below the current price at 27.01, a Stop Loss order could be placed below this zone.
Every day, new Strong Growth stocks can be found on ChartMill in our Strong Growth screener.
For an up to date full fundamental analysis you can check the fundamental report of ALKS
Our latest full technical report of ALKS contains the most current technical analsysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
ALKERMES PLC
NASDAQ:ALKS (4/26/2024, 7:00:00 PM)
After market: 24.68 0 (0%)24.68
+0.24 (+0.98%)
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to...
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—it's a hidden gem with strong fundamentals and an attractive price tag.
ALKERMES PLC (NASDAQ:ALKS) may be suited for growth investing, we'll explore why in this article.
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors...
In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.